Kamada Ltd. To Report Top-Line Data From Phase 2/3 Clinical Trial Of Inhaled AAT To Treat Alpha-1 Antitrypsin Deficiency By Late April Or Early May

Published: Mar 21, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it expects to report top-line data from the pivotal Phase 2/3 clinical trial in Europe and Canada of the Company’s proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or Inherited Emphysema) by the end of April or the beginning of May. Previously the Company expected to report the data by the end of the first quarter of 2014. Kamada plans to issue a news release in advance of the announcement of top-line data with the specific date and time of the data release.

Help employers find you! Check out all the jobs and post your resume.

Back to news